EVALUATION OF THE EFFICACY AND SAFETY OF A GLYCOSAMINOGLYCAN-PEPTIDE COMPLEX IN THE TREATMENT OF KNEE OSTEOARTHRITIS IN PATIENTS WITH PREVIOUS INEFFICIENCY OF SLOW-RELEASE ORAL ANTI-INFLAMMATORY DRUGS (THE MULTICENTER OPEN-LABEL STUDY PRIMULA: USE OF RUMALON® WITH INITIALLY SMALL SUCCESS IN THE TREATMENT OF OSTEOARTHRITIS)
https://doi.org/10.14412/1995-4484-2018-22-27
Abstract
Glycosaminoglycan-peptide complex (GPC) (Rumalon®) is an injectable slow-release anti-inflammatory agent (SRIA) that has complex anti-inflammatory and metabolic effects. GPC has been successfully used in the treatment of osteoarthritis (OA) for several decades. The agent now returns again to Russian clinical practice.
Objective: to evaluate the efficacy and tolerability of GPC in patients with knee OA, in whom other SRIAs have been previously ineffective.
Subjects and methods. A study group consisted of 104 patients (92.3% women) (mean age, 63.2±8.5 years; body mass index (BMI), 28.5±5.4 kg/m2) with severe joint pain (≥40 mm on a 100-mm visual analogue scale (VAS)) and/or the need to regularly use nonsteroidal anti-inflammatory drugs (NSAIDs). All the patients received oral SRIAs in the last 6 months and had no improvement. At baseline, VAS pain intensity was 59.4±13.1 mm; the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain was 227.3±90.8; WOMAC stiffness, 97.9±42.1; WOMAC function, 769.2±326.1; total WOMAC scores, 1095.1±426.6. GPC was used by the standard scheme: 25 intramuscular injections every other day per treatment cycle; the results of treatment were assessed at 8 and 12 weeks by VAS and WOMAC pain scores, needs for NSAIDs, satisfaction with treatment (measured on a 1- to 5-pont scale where 1 = no improvement or deterioration and 5 = the best result).
Results and discussion. At 8 and 12 weeks, VAS pain scores decreased by 30.1±18.3% and 36.9±16.9%, respectively; the reductions in WOMAC pain scores were 29.8±16.3 and 38.2±23.4%; WOMAC stiffness scores, 29.2±15.4 and 31.6±17.4%; WOMAC function scores, 27.7±14.7 and 30.6±18.4%; and total WOMAC scores, 27.2±13.5 and 33.6±18.0%. The changes in pain intensity and WOMAC scores were statistically significant in both followup periods (p<0.001). The majority of patients rated their treatment result as good or excellent: 70.2% at 8 weeks and 75.9% at 12 weeks. 31.7% of the patients completely stopped taking NSAIDs at 12 weeks. Two patients were noted to have adverse reactions (pain at the injection site and allergic skin reaction) that did not require treatment discontinuation and completely resolved without consequences after completion of a GPC treatment cycle. Conclusion. GPC is an effective and safe agent for the treatment for OA, as well as in patients with severe OA and inefficiency of oral SRIAs.
About the Authors
A. E. KarateevRussian Federation
Moscow.
L. I. Alekseeva
Russian Federation
Moscow.
A. M. Lila
Russian Federation
Moscow.
S. A. Makarov
Russian Federation
Moscow.
N. V. Chichasova
Russian Federation
Moscow.
E. V. Zonova
Russian Federation
Novosibirsk.
N. G. Kashevarova
Russian Federation
Moscow.
E. A. Taskina
Russian Federation
Moscow.
E. P. Sharapova
Russian Federation
Moscow.
References
1. Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi: 10.1038/nrdp.2016.72
2. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763
3. Балабанова РМ, Эрдес ШФ. Распространенность ревматических заболеваний в России в 2012–2013 гг. Научно-практическая ревматология. 2015;53(2):120-4 [Balabanova RM, Erdes ShF. The incidence and prevalence of rheumatic diseases in Russia in 2012–2013. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):120-4 (In Russ.)]. doi: 10.14412/1995-4484-2015-120-124
4. Фоломеева OM, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научнопрактическая ревматология. 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes ShF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(4):4-13 (In Russ.)]. doi: 10.14412/1995-4484-2008-529
5. Алексеева ЛИ, Шарапова ЕП, Кашеварова НГ, Пьяных СЕ. Новые возможности в терапии остеоартроза. Справочник поликлинического врача. 2015;(6-8):4-7 [Alekseeva LI, Sharapova EP, Kashevarova NG, P'yanykh SE. New possibilities in the therapy of osteoarthritis. Spravochnik Poliklinicheskogo Vracha. 2015;(6-8):4-7 (In Russ.)].
6. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis: From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.
7. Klein R, Becker EW, Berg PA, Bernau A. Immunomodulatory properties of rumalon, a glycosaminoglycan peptide complex, in patients with osteoarthritis: activation of T helper cell type 2 cytokines and antigen-specific IgG4 antigen-specific igG4 antibodies. J Rheumatol. 2000 Feb;27(2):448-54.
8. Vignon E, Martin A, Mathieu P, et al. Study of the effect of a glycosaminoglycan-peptide complex on the degradative enzyme activities in human osteoarthritic cartilage. Clin Rheumatol. 1990 Sep;9(3):383-8. doi: 10.1007/BF02114400
9. Bouakka M, Loyau G, Bocquet J. Effect of a glycosaminoglycanpeptide complex on the biosynthesis of protoglycans in articular chondrocytes treated with interleukin-1. Curr Ther Res. 1988;43:588-99.
10. Annefeld M, Erne B. The mode of action of a glycosaminoglycanpeptide-complex (Rumalon) on articular cartilage of the rat in vivo. Clin Rheumatol. 1987 Sep;6(3):340-9. doi: 10.1007/BF02206832
11. Насонова ВА. Диагностика и лечение больных пожилого возраста, страдающих манифестным остеоартрозом. Русский медицинский журнал. 2001;(3):157-62 [Nasonova VA. Diagnosis and treatment of elderly patients suffering from manifest osteoarthritis. Russkii Meditsinskii Zhurnal. 2001;(3):157-62 (In Russ.)].
12. Altman RD. Measurement of structure (disease) modification in osteoarthritis. Osteoarthritis Cartilage. 2004;12 Suppl A:S69-76.
13. Rejholec V, Kralova M. [Long-term treatment of coxarthrosis using Rumalon. Comparative study on 224 patients, observation period of 8 years]. Z Rheumatol. 1974 Nov-Dec;33(11-12):425-36 (In Germ.).
14. Rejholec V, Kralova M. Langzeitbehandlung der Coxarthrose mit Rumalon®. Akt Rheumatol. 1984;9:139-48. doi: 10.1055/s-2008-1048133
15. Adler E, Wolf E, Taustein I. A double blind trial with cartilage and bone marrow extract in degenerative gonarthrosis. Scand J Rheumatol. 1987;16(1):6-11. doi: 10.3109/03009747009165349
16. Gramajo RJ, Cutroneo EJ, Fernandez DE, et al. A single-blind, placebo-controlled study of glycosaminoglycan-peptide complex ('Rumalon') in patients with osteoarthritis of the hip or knee. Curr Med Res Opin. 1989;11(6):366-73. doi: 10.1185/03007998909110137
17. Katona G. A clinical trial of glycosaminoglycan-peptide complex ('Rumalon') in patients with osteoarthritis of the knee. Curr Med Res Opin. 1987;10(9):625-33. doi: 10.1185/03007998709112416
18. Алексеева ЛИ, Карякин АН, Смирнов АВ, Беневоленская ЛИ. Применение Румалона при гонартрозе. Терапевтический архив. 1997;(5):64-6 [Alekseeva LI, Karyakin AN, Smirnov AV, Benevolenskaya LI. Application of Rumalon in gonarthrosis. Terapevticheskii Arkhiv. 1997;(5):64-6 (In Russ.)].
19. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9
20. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012 Aug;51(2):249-57. doi: 10.1016/j.bone.2012.02.012. Epub 2012 Feb 22.
21. McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015 Jan;54(1):29-38. doi: 10.1093/rheumatology/keu328. Epub 2014 Sep 16.
22. McGonagle D, Aydin SZ, Tan AL. The synovio-entheseal complex and its role in tendon and capsular associated inflammation. J Rheumatol. 2012 Jul;89 Suppl:11-4. doi: 10.3899/jrheum.120233
23. Benjamin M, McGonagle D. Histopathologic changes at «synovio-entheseal complexes» suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum. 2007 Nov;56(11):3601-9. doi: 10.1002/art.23078
Review
For citations:
Karateev A.E., Alekseeva L.I., Lila A.M., Makarov S.A., Chichasova N.V., Zonova E.V., Kashevarova N.G., Taskina E.A., Sharapova E.P. EVALUATION OF THE EFFICACY AND SAFETY OF A GLYCOSAMINOGLYCAN-PEPTIDE COMPLEX IN THE TREATMENT OF KNEE OSTEOARTHRITIS IN PATIENTS WITH PREVIOUS INEFFICIENCY OF SLOW-RELEASE ORAL ANTI-INFLAMMATORY DRUGS (THE MULTICENTER OPEN-LABEL STUDY PRIMULA: USE OF RUMALON® WITH INITIALLY SMALL SUCCESS IN THE TREATMENT OF OSTEOARTHRITIS). Rheumatology Science and Practice. 2018;56(1):22-27. (In Russ.) https://doi.org/10.14412/1995-4484-2018-22-27